GlassScriptPhysician profile
Jose Gilberto Quijada
NPI 1457700049
$751.64
in general payments reported to CMS, 2019-2025
11 companies · $327 in 2025
The $327 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.89 · 2021: $90.34 · 2022: $24.89 · 2023: $106 · 2024: $190 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $226.01 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $120.64 | 2023-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $94.09 | 2021-2023 | Vaxneuvance, Rotateq, Vaqta |
| Cranial Technologies, INC | $68.60 | 2023-2024 | Doc Band |
| Sanofi Pasteur INC. | $63.86 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $56.66 | 2025 | Jornay Pm |
| Phadia US INC. | $37.18 | 2025 | Immunocap |
| Boston Scientific Corporation | $31.05 | 2025 | Watchman Flx |
| Cipher Pharmaceuticals US LLC | $20.58 | 2025 | Natroba, Spinosad |
| Takeda Pharmaceuticals U.S.A., INC. | $16.98 | 2021 | |
| Glaxosmithkline, LLC. | $15.99 | 2025 | Rotarix, Pediarix, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Quijada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.